



Executive Committee



Roch Doliveux

Chief Executive Officer and Chairman of the Executive Committee

- Joined UCB in October 2003
- Appointed in January 2005

Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA from INSEAD (France) with distinction.

He joined the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in France, and then at Schering-Plough Corporation in various positions, including President of Schering-Plough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of Pierre Fabre Pharmaceuticals.

Roch Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, a member of the Board of Stryker Corporation in the US, as well as a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, WELBIO (Walloon Institute for Life Lead Sciences), the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund (King Baudouin Foundation).

Roch Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in October 2011.